Logo image of ANRO

ALTO NEUROSCIENCE INC (ANRO) Stock Fundamental Analysis

USA - NYSE:ANRO - US02157Q1094 - Common Stock

15.54 USD
+0.79 (+5.36%)
Last: 11/19/2025, 2:57:27 PM
15.14 USD
-0.4 (-2.57%)
Pre-Market: 11/20/2025, 8:00:41 AM
Fundamental Rating

2

Overall ANRO gets a fundamental rating of 2 out of 10. We evaluated ANRO against 192 industry peers in the Pharmaceuticals industry. ANRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ANRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANRO has reported negative net income.
In the past year ANRO has reported a negative cash flow from operations.
ANRO Yearly Net Income VS EBIT VS OCF VS FCFANRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -42.35%, ANRO is in line with its industry, outperforming 42.71% of the companies in the same industry.
The Return On Equity of ANRO (-55.81%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.35%
ROE -55.81%
ROIC N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANRO Yearly ROA, ROE, ROICANRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANRO Yearly Profit, Operating, Gross MarginsANRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for ANRO has been increased compared to 1 year ago.
The debt/assets ratio for ANRO has been reduced compared to a year ago.
ANRO Yearly Shares OutstandingANRO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANRO Yearly Total Debt VS Total AssetsANRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ANRO has an Altman-Z score of 4.93. This indicates that ANRO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.93, ANRO is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
A Debt/Equity ratio of 0.20 indicates that ANRO is not too dependend on debt financing.
ANRO's Debt to Equity ratio of 0.20 is in line compared to the rest of the industry. ANRO outperforms 45.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 4.93
ROIC/WACCN/A
WACCN/A
ANRO Yearly LT Debt VS Equity VS FCFANRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 15.42 indicates that ANRO has no problem at all paying its short term obligations.
ANRO's Current ratio of 15.42 is amongst the best of the industry. ANRO outperforms 88.54% of its industry peers.
ANRO has a Quick Ratio of 15.42. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 15.42, ANRO belongs to the best of the industry, outperforming 88.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.42
Quick Ratio 15.42
ANRO Yearly Current Assets VS Current LiabilitesANRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.51% over the past year.
EPS 1Y (TTM)76.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.48% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.03%
EPS Next 2Y1.66%
EPS Next 3Y0.76%
EPS Next 5Y4.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANRO Yearly Revenue VS EstimatesANRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 200M 400M 600M
ANRO Yearly EPS VS EstimatesANRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANRO. In the last year negative earnings were reported.
Also next year ANRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANRO Price Earnings VS Forward Price EarningsANRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANRO Per share dataANRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.66%
EPS Next 3Y0.76%

More info and screens

0

5. Dividend

5.1 Amount

ANRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTO NEUROSCIENCE INC

NYSE:ANRO (11/19/2025, 2:57:27 PM)

Premarket: 15.14 -0.4 (-2.57%)

15.54

+0.79 (+5.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-20 2026-03-20/amc
Inst Owners62.9%
Inst Owner Change-2.84%
Ins Owners7.48%
Ins Owner Change0%
Market Cap420.82M
Revenue(TTM)N/A
Net Income(TTM)-62.26M
Analysts85.33
Price Target30.16 (94.08%)
Short Float %12.48%
Short Ratio1.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.85%
Min EPS beat(2)-3.96%
Max EPS beat(2)23.65%
EPS beat(4)3
Avg EPS beat(4)11.23%
Min EPS beat(4)-3.96%
Max EPS beat(4)23.65%
EPS beat(8)5
Avg EPS beat(8)-44.16%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)81.11%
PT rev (3m)81.11%
EPS NQ rev (1m)3.43%
EPS NQ rev (3m)-1.42%
EPS NY rev (1m)2.89%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.77
P/tB 3.77
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.97
OCFYN/A
SpS0
BVpS4.12
TBVpS4.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.35%
ROE -55.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.42
Quick Ratio 15.42
Altman-Z 4.93
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)251.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y1.03%
EPS Next 2Y1.66%
EPS Next 3Y0.76%
EPS Next 5Y4.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.07%
EBIT Next 3Y-23.96%
EBIT Next 5Y-14.66%
FCF growth 1Y-91.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.64%
OCF growth 3YN/A
OCF growth 5YN/A

ALTO NEUROSCIENCE INC / ANRO FAQ

What is the ChartMill fundamental rating of ALTO NEUROSCIENCE INC (ANRO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANRO.


Can you provide the valuation status for ALTO NEUROSCIENCE INC?

ChartMill assigns a valuation rating of 0 / 10 to ALTO NEUROSCIENCE INC (ANRO). This can be considered as Overvalued.


How profitable is ALTO NEUROSCIENCE INC (ANRO) stock?

ALTO NEUROSCIENCE INC (ANRO) has a profitability rating of 1 / 10.


Can you provide the financial health for ANRO stock?

The financial health rating of ALTO NEUROSCIENCE INC (ANRO) is 6 / 10.